Member Profile
ACT Genomics
ACT Genomics is a world-leading cancer solution provider. We offer precision medicine services in Taiwan, Singapore, Hong Kong, and Japan. We combine our expertise in tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation. Through cutting-edge next-generation sequencing (NGS) platforms, CAP/LDTS-accredited laboratory, bioinformatics analysis, and comprehensive service offerings, we seek to convert every cancer patient’s genetic information into actionable solutions.
Company Milestones
| 2014 | ACT Genomics was founded and opened ACT Genomics NGS laboratory |
| 2015 | Established ACT Genomics Singapore branch |
| 2016 | Received CAP Accreditation |
| 2016 | Granted the Symbol of National Quality Award in the Biotechnology Service Category |
| 2016 | Established ACT Genomics Hong Kong branch and Shanghai branch |
| 2017 | ACT Genomics Received 2017 Frost & Sullivan Asia Pacific Molecular Diagnostics Product Line Strategy Leadership Award |
| 2017 | Established ACT Genomics Japan branch |
| 2018 | ACT Genomics joins TMB Harmonization Project to standardize the calculation of tumor mutational burden |
| 2018 | Canon Medical System Corporation officially acquired ACT Genomics’ joint venture company in Japan, ACTmed |
| 2019 | ACT Genomics Establishes NGS Laboratory to Offer Comprehensive Cancer Genomic Profiling Service in Japan |
| 2019 | ACT Genomics opened its third Next Generation Sequencing laboratory in Asia at the Hong Kong Science Park |
| 2020 | ACT Genomics is the first to receive approval for laboratory-developed NGS tests and services (LDTS) in Taiwan |
| 2020 | Acquires ISO/IEC 27001 certification |
| 2021 | ACT Genomics completes acquisition of MC Diagnostics |
| 2021 | CerbACT Asia – a joint venture between ACT Genomics and Cerba Research – is formed to establish a new and top-notched facility in Taipei |
| 2021 | ACT Genomics acquires Sanomics |